Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenue	$ 17,026	$ 9,614	$ 44,721	$ 23,087
Cost of goods sold	4,170	2,882	11,206	7,207
Gross profit	12,856	6,732	33,515	15,880
Operating expenses:
Research and development	3,187	2,442	9,008	6,868
Selling, general and administrative	17,064	8,973	45,064	23,108
Total operating expenses	20,251	11,415	54,072	29,976
Loss from operations	(7,395)	(4,683)	(20,557)	(14,096)
Interest income	565	28	1,215	65
Interest expense	(1,176)	(1,065)	(3,736)	(3,065)
Other income (expense), net	(1)	(3,233)	(21,046)	(4,915)
Net loss	(8,007)	(8,953)	(44,124)	(22,011)
Comprehensive loss	(8,007)	(8,953)	(44,124)	(22,011)
Net loss attributable to non-controlling interest	0	1	0	1
Comprehensive loss attributable to non-controlling interest	0	1	0	1
Net loss attributable to Silk Road Medical, Inc. common stockholders	(8,007)	(8,952)	(44,124)	(22,010)
Comprehensive loss attributable to Silk Road Medical, Inc. common stockholders	$ (8,007)	$ (8,952)	$ (44,124)	$ (22,010)
Net loss per share, basic and diluted (in USD per share)	$ (0.26)	$ (8.49)	$ (2.18)	$ (24.14)
Weighted average common shares used to compute net loss per share, basic and diluted (in shares)	30,764,354	1,054,794	20,249,580	911,873